DUSA Pharmaceuticals to Present at CIBC World Markets 17th Annual Healthcare Conference

The i-Technology Media!	Register \| Log in

.NET · AJAX · CLOUD · ECLIPSE · FLEX · OPEN WEB · iPHONE · JAVA · LINUX · OPEN SOURCE · ORACLE · PBDJ · SEARCH · SILVERLIGHT · SOA · VIRTUALIZATION · WEB 2.0 · WIRELESS · XML

Comments

Improving the Efficiency of SOA-Based Applications

jhv1blz5 wrote: The article validated SOA as an IT architecture paradigm that can be leveraged in many ways. Taking data storage, scalability and application performance to a nifty level using SOA Application Grid infrastructure will no doubt enhance data and application performance on Oracle architecture platforms, it also has the promise of a cost effective and efficient IT delivery model. The very benefits of SOA.

Jul. 3, 2009 10:31 AM EDT

Cloud Computing | Virtualization
November 2 - 4
Register Today and SAVE !..

Did you read today's front page stories & breaking news?

Live Google News by SYS-CON!

Top Three Links You Must Click On

From the Wires

DUSA Pharmaceuticals to Present at CIBC World Markets 17th Annual Healthcare Conference

By: Marketwire .

Nov. 1, 2006 06:42 PM

WILMINGTON, MASSACHUSETTS -- (MARKET WIRE) -- 11/01/06 -- DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA), today announced that Dr. Geoff Shulman, Chairman and CEO and Mr. Bob Doman, President and COO, will present a corporate overview at the CIBC World Markets 17th Annual Healthcare Conference on Monday, November 6, 2006 at 4:25 p.m. ET at The Waldorf-Astoria Hotel in New York.

Interested investors can access the live audio webcast of the presentation at www.dusapharma.com. An archived version of the presentation will be available on the DUSA website for 14 days following the presentation.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of pre-cancerous actinic keratoses, and is being developed for the treatment of acne and photodamage. DUSA's other dermatology products include Nicomide®, and the AVAR® line, resulting from its merger with Sirius Laboratories, Inc. These products target patients with acne and rosacea. DUSA is also developing certain internal indications of Levulan PDT. DUSA is based in Wilmington, MA. Please visit our website at www.dusapharma.com.

Contacts:
DUSA Pharmaceuticals, Inc.
Shari Lovell
Director, Shareholder Services
(416) 363-5059
(416) 363-6602 (FAX)
Website: www.dusapharma.com

Published Nov. 1, 2006
Copyright © 2006 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.

About Marketwire .
Copyright © 2009 Marketwire. All rights reserved. All the news releases provided by Market Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.